Azitra Q2 net loss narrows to $2.6M; completes $10M offering, pipeline milestones set

Azitra, Inc.

2024-Q2 EPS reported -$6.82 revenue$7,500

Net loss of $2.6M improved from $5.1M in Q2 2023; cash and equivalents $0.8M as of June 30.
Completed $10M follow-on offering, expected to fund operations into 2025.
R&D expenses $1.1M (up from $0.8M); G&A $1.5M (up from $0.8M); service revenue $7,500 (down from $172k).
Expects to dose first Netherton syndrome patient with ATR-12 in Q3 2024; plans IND for ATR-04 for EGFRi rash.
Anticipates initial safety data from ATR-12 Phase 1b by year-end 2024, topline data by mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.